Dr Johanna Laru, Associate Director, Pharmaceutical Sciences, R&D at AstraZeneca commented: “We know the best science doesn’t happen in isolation. This grant builds on our existing collaboration with the University of Nottingham, Quotient Sciences Ltd and Added Scientific Ltd, and we look forward to working together to further assess the potential of 3D printing in the medicines development.”
“The scope for 3D printing in the pharmaceutical industry is significant, with potential applications including the rapid development of prototype dosage forms and the ability to personalise drug products to individual patient needs, for example in rare, orphan and paediatric diseases,” said Dr Peter Scholes, Chief Scientific Officer at Quotient Sciences. “We are excited to be part of this collaborative program which will look to translate the research performed at the University of Nottingham into an industrial manufacturing setting”.
Tim Setchfield, General Manager of Added Scientific said: “Added Scientific are very excited to be part of this work after our involvement in an earlier collaborative project looking at the feasibility of printing pills. The opportunity to observe, learn and benefit from the first human trials of this technology will be invaluable to the company and our engineers and scientists.”